These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 4032403)

  • 1. Abnormal bowel permeability in ankylosing spondylitis and rheumatoid arthritis.
    Smith MD; Gibson RA; Brooks PM
    J Rheumatol; 1985 Apr; 12(2):299-305. PubMed ID: 4032403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives.
    Vaile JH; Meddings JB; Yacyshyn BR; Russell AS; Maksymowych WP
    J Rheumatol; 1999 Jan; 26(1):128-35. PubMed ID: 9918253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease.
    Mielants H; De Vos M; Goemaere S; Schelstraete K; Cuvelier C; Goethals K; Maertens M; Ackerman C; Veys EM
    J Rheumatol; 1991 Mar; 18(3):394-400. PubMed ID: 1906939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Determination of endotoxin in inflammatory rheumatic diseases--the effect of nonsteroidal anti-inflammatory agents on intestinal permeability].
    Busch J; Hammer M; Brunkhorst R; Wagener P
    Z Rheumatol; 1988; 47(3):156-60. PubMed ID: 3213262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of intestinal permeability in the pathogenesis of ankylosing spondylitis].
    Liu Y; Xu B; Cai X
    Zhonghua Nei Ke Za Zhi; 1995 Feb; 34(2):91-4. PubMed ID: 7796664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole body retention of diphosphonate in rheumatoid arthritis.
    Steven MM; Sturrock RD; Fogelman I; Smith ML
    J Rheumatol; 1982; 9(6):873-7. PubMed ID: 7161778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of the preparation Donalgin in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Sadkiewicz S; Barwik-Schramm A; Grzywa M; Letkiewicz C; Piotrowska E; Procel Z; Reszkowska H; Wippel A; Woźniak M; Zmudzińska I
    Reumatologia; 1982; 20(1-2):75-80. PubMed ID: 6761815
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical studies in the field of degenerative joint diseases with a phenylalcanoic derivative].
    Manfredi GC
    Minerva Med; 1973; 64(48):2561-4. PubMed ID: 4580158
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis.
    Lignière GC; Colombo B; Carrabba M; Ferrari P; Robotti E
    Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:253-8. PubMed ID: 4553232
    [No Abstract]   [Full Text] [Related]  

  • 10. [Use of Eumotol in the treatment of rheumatic diseases].
    Zimmermann-Górska I; Konieczna B
    Reumatologia; 1973; 11(3):305-8. PubMed ID: 4748105
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibodies to Klebsiella, Proteus, and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis.
    Tani Y; Tiwana H; Hukuda S; Nishioka J; Fielder M; Wilson C; Bansal S; Ebringer A
    J Rheumatol; 1997 Jan; 24(1):109-14. PubMed ID: 9002020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of inflammation related gene expression spectrum in ankylosing spondylitis patients using cDNA microarray].
    Gu J; Huang F; Yu D
    Zhonghua Yi Xue Za Zhi; 2001 Sep; 81(17):1030-4. PubMed ID: 11758249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Various indicators of the effectiveness of long-term ambulatory treatment of rheumatoid arthritis and Bechterew's disease].
    Aseeva EM; Kheĭman KG; Karpova AA; Mozgovaia MA; Al'bam EA
    Ter Arkh; 1979; 51(7):110-3. PubMed ID: 494075
    [No Abstract]   [Full Text] [Related]  

  • 14. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal mucosal permeability in inflammatory rheumatic diseases. I. Role of antiinflammatory drugs.
    Mielants H; Goemaere S; De Vos M; Schelstraete K; Goethals K; Maertens M; Ackerman C; Veys EM
    J Rheumatol; 1991 Mar; 18(3):389-93. PubMed ID: 1906938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of solasodin in the treatment of some internal diseases].
    Milimovka ME; Konovalov MN; Boĭdykh RI; Kazakov MG; Rybnikov NI; Strizhevskaia AZ
    Vrach Delo; 1966 May; 5():62-5. PubMed ID: 5995513
    [No Abstract]   [Full Text] [Related]  

  • 17. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M; Sebald HJ; Villiger PM; Hofstetter W; Seitz M
    Ann Rheum Dis; 2008 May; 67(5):620-4. PubMed ID: 17720725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin and growth hormone responses to hypoglycemia in patients with rheumatoid arthritis and ankylosing spondylitis.
    Rovensky J; Imrich R; Malis F; Zlnay M; Macho L; Koska J; Vigas M
    J Rheumatol; 2004 Dec; 31(12):2418-21. PubMed ID: 15570644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal permeability in ankylosing spondylitis.
    Wendling D; Bidet A; Guidet M
    J Rheumatol; 1990 Jan; 17(1):114-5. PubMed ID: 2313660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.